| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/26/2005 | WO2005046648A1 Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine |
| 05/26/2005 | WO2005046623A1 Combined cosmetic or therapeutic preparation |
| 05/26/2005 | WO2005046617A2 Compositions and methods for reducing microbial induced apoptosis |
| 05/26/2005 | WO2005046594A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | WO2005046567A2 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same |
| 05/26/2005 | WO2005046562A2 Use of sulfated hyaluronic acid |
| 05/26/2005 | WO2005046318A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | WO2005030225A3 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 05/26/2005 | WO2005027951B1 Method for controlling angiogenesis in animals |
| 05/26/2005 | WO2005020901A3 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 05/26/2005 | WO2005013957A3 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 05/26/2005 | WO2005007082A3 Treatment of chronic bacterial infection |
| 05/26/2005 | WO2005000331A3 Compositions for the treatment and prevention of degenerative joint disorders |
| 05/26/2005 | WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 05/26/2005 | WO2004062604A3 Treatment of cancer with 2-deoxyglucose |
| 05/26/2005 | WO2004039321A8 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
| 05/26/2005 | WO2003077841A3 Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| 05/26/2005 | WO2002093998A9 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 05/26/2005 | US20050114914 linker for activation of T- cells (lat genes and proteins), used for screening drug useful for treatment against asthma and allergies |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113433 Diagnosing a subject in need of hemorrhagic or ischemic stroke treatment; administering 2-(N-anilino-)phenylacetic acid; |
| 05/26/2005 | US20050113427 Use of peroxynirite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence |
| 05/26/2005 | US20050113421 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders |
| 05/26/2005 | US20050113384 Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents |
| 05/26/2005 | US20050113381 Pyridazinone aldose reductase inhibitors |
| 05/26/2005 | US20050113367 Mixture of angiotensin II receptor antagonist and diuretics (a thiazide); hypotensive agents; low toxicity |
| 05/26/2005 | US20050113365 Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
| 05/26/2005 | US20050113362 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 05/26/2005 | US20050113354 Bioavailable prodrugs of androgenic steroids and related method |
| 05/26/2005 | US20050113333 Comprises caffeic acid, chlorogenic acid, and/or ferulic acid, water-soluble and fermentable dietary fiber (alginate, polydextrose) |
| 05/26/2005 | US20050113331 Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors |
| 05/26/2005 | US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization |
| 05/26/2005 | US20050113321 DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor |
| 05/26/2005 | US20050113318 Such as salmeterol or formoterol; low amounts of active agents, less prone to detrimental side effects |
| 05/26/2005 | US20050113317 Such as cromolyn sodium or nedocromil sodium; low amounts of active agents, less prone to detrimental side effects |
| 05/26/2005 | US20050113314 For treating microalbuminuria, nephropathies, retinopathies, and erectile dysfunction; side effect reduction |
| 05/26/2005 | US20050113307 Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| 05/26/2005 | US20050113306 For inhibition of bone metastases in prostate cancer patients |
| 05/26/2005 | US20050113303 Method for treating metabolic bone disease such as osteomalacia and osteoporosis in a patient by administering a compound that modulates phosphate regulating endopeptidase homolog (PEX) expression and/or PEX enzymatic activity |
| 05/26/2005 | US20050113301 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis |
| 05/26/2005 | US20050113295 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113294 Carboxamide and amino derivatives and methods of their use |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050113290 Method and composition for treating cancer by converting soluble radioactive toxic agents into insoluble radioactive toxic precipitates via the action of non-mammalian enzymes bound to the non-endocytosing receptors of target cells |
| 05/26/2005 | US20050113287 Composition to enhance joint function and repair |
| 05/26/2005 | US20050113284 Drug for regenerating tissue and vessel and method therefor |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112709 Histone h3methyltransferase polypeptide |
| 05/26/2005 | US20050112681 Isolated human transporter proteins, nucleic acid molecules encoding human, transporter proteins, and uses thereof |
| 05/26/2005 | US20050112596 APRIL-A novel protein with growth effect |
| 05/26/2005 | US20050112574 Isolated nucleic acid; angiogenesis inhibitor |
| 05/26/2005 | US20050112570 Indicator for development of diabetes |
| 05/26/2005 | US20050112568 Dgks as modifiers of the p53 pathwha and methods of use |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112210 Age-related macular degeneration; include vitamins, minerals, and antioxidants such as vitamins A, C, E, zinc, lutein and zeaxanthin |
| 05/26/2005 | US20050112208 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112202 tableting processes and equipment, and improved solid dosage forms for oral delivery of drugs that cause contact irritation or ulceration to the lining of the esophagus and stomach |
| 05/26/2005 | US20050112199 Therapeutic regimens for administering drug combinations |
| 05/26/2005 | US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics |
| 05/26/2005 | US20050112175 Drug delivery device |
| 05/26/2005 | US20050112173 In vivo synthesis of connective tissues |
| 05/26/2005 | US20050112146 Administering neurotoxin to infants; cerebral palsy therapy |
| 05/26/2005 | US20050112128 Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure |
| 05/26/2005 | US20050112127 Treating with active material having heavy chain variable region of amino acid sequence 7 and light chain variable region of sequence 8; psoriasis, multiple sclerosis, Crohn's disease |
| 05/26/2005 | US20050112120 Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 05/26/2005 | US20050112117 Molecules and methods for inhibiting shedding of KIM-1 |
| 05/26/2005 | US20050112111 Microbiological culturein aqueous solution containing nutrients; probiotic activity |
| 05/26/2005 | US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators |
| 05/26/2005 | US20050112106 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| 05/26/2005 | US20050112091 Osteoporosis mixture of bone forming agents and nonabsorbent |
| 05/26/2005 | US20050112079 Administering andothelins, or antagonist thereof, as drug or cosmetics for hair removal or wool harvesting |
| 05/26/2005 | US20050112071 Hypoestoxides, derivatives, agonists and crude extracts thereof for use in cosmetic compositions |
| 05/26/2005 | US20050112069 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist |
| 05/26/2005 | US20050112066 Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
| 05/26/2005 | US20050112021 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light |
| 05/26/2005 | US20050109981 Neutralize biological pathogens; sterilization of medical equipment; food processing equipment; mixture of bleaching activator, base and water |
| 05/26/2005 | CA2545771A1 Migraine treatments including isovaleramide compounds and serotonin agonists |
| 05/26/2005 | CA2545731A1 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 05/26/2005 | CA2545204A1 Compositions of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels |
| 05/26/2005 | CA2545117A1 Virucidal activities of a combination of cetylpyridinium chloride and citric acid |
| 05/26/2005 | CA2545058A1 4-biarylyl-1-phenylazetidin-2-ones |
| 05/26/2005 | CA2544621A1 Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
| 05/26/2005 | CA2544603A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | CA2544591A1 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 05/26/2005 | CA2544421A1 Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| 05/26/2005 | CA2544309A1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| 05/26/2005 | CA2544245A1 Use of selective opiate receptor modulators in the treatment of neuropathy |
| 05/26/2005 | CA2543806A1 Combined cosmetic or therapeutic preparation |
| 05/26/2005 | CA2543596A1 Hdl-boosting combination therapy complexes |
| 05/26/2005 | CA2543582A1 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 05/25/2005 | EP1532986A2 Pharmaceutical composition for treatment of rhinitis |
| 05/25/2005 | EP1532434A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 05/25/2005 | EP1532278A2 Diagnosis of chronic rejection |
| 05/25/2005 | EP1532269A2 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
| 05/25/2005 | EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 05/25/2005 | EP1532250A1 Fcyriia transgenic animal model for autoimmune disease |
| 05/25/2005 | EP1532246A2 Genetic suppression and replacement |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532153A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |